Excision BioTherapeutics

About

Excision BioTherapeutics is a biotechnology company founded in 2015, focused on developing CRISPR-based gene-editing therapies to address viral infectious diseases such as HIV, herpes simplex viruses, and hepatitis B. Headquartered in San Francisco, the company utilizes proprietary CRISPR-Cas9 technology to target and inactivate viral DNA in infected cells, advancing multiple programs toward clinical trials. The company's lead product, EBT-101, is a CRISPR-Cas9 therapy for HIV that is currently under clinical investigation and has received FDA fast-track status. EBT-107 targets chronic hepatitis B and has shown positive preclinical results. Excision is also developing therapies for herpes simplex viruses, building on its initial successes in HIV research. The company collaborates with prominent institutions and has garnered support from notable experts in the field.